Zelin Sheng

US Patent:

20030215787, Nov 20, 2003

Filed:

Jan 23, 2003

Appl. No.:

10/349670

Inventors:

Wen-Pin Yang - Princeton NJ, US
Anita Knapp-Ryseck - Titusville NJ, US
Yuli Wu - Newtown PA, US
Jinwen Huang - West Windsor NJ, US
Stephen Walker - East Windsor NJ, US
Jian Chen - Princeton NJ, US
Stephen Kalinowski - Levittown PA, US
Zelin Sheng - Belle Mead NJ, US
Samuel Hellings - Levittown PA, US

International Classification:

A61K031/00
C12Q001/00

US Classification:

435/004000, 514/001000

Abstract:

The present invention relates to compounds which act as modulators of the chloride channel CLC-7, assays for the identification of such compounds and methods of preventing, diagnosing, and treating osteoporosis and related disease states using such compounds.

US Patent:

20080242596, Oct 2, 2008

Filed:

Apr 1, 2008

Appl. No.:

12/060767

Inventors:

Yuanwei Chen - North Haven CT, US
Yan Feng - Shanghai, CN
Baihua Xu - Shanghai, CN
Binhua Lv - Shanghai, CN
Brian Seed - Derry NH, US
Michael J. Hadd - San Diego CA, US
Huawei Cheng - Shanghai, CN
Zelin Sheng - Belle Mead NJ, US
Min Xu - Shanghai, CN
Congna Wang - Shanghai, CN
Jiyan Du - Shanghai, CN
Lili Zhang - Shanghai, CN
Ge Xu - Shanghai, CN
Yuelin Wu - Shanghai, CN

Assignee:

Theracos, Inc. - Sunnyvale CA

International Classification:

A61K 38/28
C07H 7/04
A61P 3/10
A61K 31/7034

US Classification:

514 4, 536122, 514 23

Abstract:

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.